title: Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices.
abstract: BACKGROUND
  The use of indwelling central venous catheters (CVCs) has become commonplace in the management of children undergoing anticancer treatment. Several types of CVC are available, while information on complications observed in children is scarce. We describe the experience of two tertiary care centers in Italy that prospectively followed up three types of CVC used at both institutions over a 30-month period.
  
  
  METHODS
  Between January 2000 and May 2002, double-lumen (DL) or single-lumen (SL) Hickman-Broviac (HB) catheters, and single-lumen pressure-activated safety valve (PASV) catheters were used and prospectively evaluated. Four types of possible complication were defined a priori: mechanical, thrombotic, malfunctioning and infectious.
  
  
  RESULTS
  Four hundred and eighteen CVCs (180 SL-HB, 162 DL-HB and 76 PASV) were inserted in 368 children, for a total of 107 012 catheter days at risk of complication. At least one complication occurred while using 169 of the devices (40%): 46% of the DL-HB, 46% of the PASV and 33% of the SL-HB (P=0.02) catheters. Subjects with hematological malignancies or non-malignant diseases had significantly more complications than those with solid tumors (P <0.0001). Overall, 234 complications were documented: 93 infectious [complication rate per 1000 catheter days at risk (CR)=0.87], 84 malfunctioning (CR=0.78), 48 mechanical (CR=0.45) and nine thrombotic (CR=0.08). SL-HB had statistically fewer infectious complications, while PASV had more mechanical complications. In a multivariate regression model, the most significant risk factors for having a CVC complication were hematological disease [relative risk (RR)=3.0; 95% confidence interval (CI) 1.8-4.8] and age <6 years at CVC insertion (RR=2.5; 95% CI 1.5-4.1). As for the type of CVC, compared with SL-HB, the DL-HB catheter had a statistically significant two-fold increased risk of any complication (RR=2.1; 95% CI 1.2-3.6), while the PASV catheter had a borderline RR of 1.8 (95% CI 1.0-3.6). Analysis by tumor type showed a higher risk of any kind of complication in patients with solid malignancies who had received a DL-HB catheter as compared with an SL-HB catheter (RR=7.2; 95% CI 2.8-18.7).
  
  
  CONCLUSIONS
  CVCs may cause complications in up to 40% of patients, with type of CVC, underlying disease and patient age being the three main factors that affect the incidence of CVC-related complications. SL-HB catheters have the best performance.
authors.affiliation: Department of Pediatric Surgery, G. Gaslini Children's Hospital, Genoa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fratino
authors.forename: A C
authors.initials: AC
authors.lastname: Molinari
authors.forename: S
authors.initials: S
authors.lastname: Parodi
authors.forename: S
authors.initials: S
authors.lastname: Longo
authors.forename: P
authors.initials: P
authors.lastname: Saracco
authors.forename: E
authors.initials: E
authors.lastname: Castagnola
authors.forename: R
authors.initials: R
authors.lastname: Haupt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000295:instrumentation; D002648:Child; D016001:Confidence Intervals; D004866:Equipment Contamination / Q000517:prevention & control; D005260:Female; D006402:Hematologic Diseases / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000150:complications / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D013927:Thrombosis / Q000150:complications / Q000517:prevention & control / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents